1. MOnoclonal antibodies and potential applications in migraine

2. Introduction to mAbs

3. What Is CGRP and What Is Its Function?

4. CGRP Receptor Antagonists in Migraine

5. mAb Development: History

6. Evolution of Therapeutic mAbs

7. Normal Antibody Production

8. What Is an Antibody?

9. Five Different Antibody Isotypes in Humans

10. Antibody Types

11. Antibodies and IgG

12. IgG Subclasses

13. Therapeutic mAbs

14. Polyclonal Antibodies vs mAbs

15. Naming Conventions for mAbs

16. Naming Conventions for Therapeutic mAbs: Species

17. Therapeutic mAbs: Direct and Indirect Mechanisms of Action

18. mAb Metabolism and Elimination

19. FcRn and Antibody Half-life

20. Pharmacokinetics of mAbs

21. Tolerability of mAbs

22. Benefits of mAbs

23. mAbs vs Small Molecules

24. CGRP

25. CGRP Receptor Mechanisms

26. CGRP and Its Related Receptor Family

27. Antibody Binding to Receptor Complex

28. Specificity of Anti-CGRP Pathway mAbs

29. Small-Molecule CGRP Antagonists vs mAbs

30. New CGRP Antibody Antagonists

31. Anti-CGRP Pathway mAbs in Development: Characteristics

32. Efficacy and Tolerability of Anti-CGRP Pathway mAbs in Phase 2 Studies

33. Summary of Efficacy and Tolerability in Phase 2 Trials

34. Concluding Remarks

35. Abbreviations

36. Abbreviations